The FDA weigh up mandatory education for opioid prescribers; There’s an increase in the sale of strong psychoactive THC products; Brukinsa and Exkivity gain approval, respectively; And a number of supplement companies received FDA warning letters.
The FDA has not evaluated these products for safety or effectiveness.
Remission defined as HbA1c <6.5 percent for at least three months after cessation of glucose-lowering pharmacotherapy
In FIDELITY, investigators pooled data from more than 13,000 patients from the FIDELIO-DKD and FIGARO-DKD trials.
Secondary analysis of randomized trial shows no difference in progression of KDIGO risk scores with daily vitamin D versus placebo
Overweight or obese adults should be screened for prediabetes, type 2 diabetes and offered or referred for preventive interventions
The FDA has approved the new Gvoke® Kit formulation for the treatment of severe hypoglycemia in patients with diabetes 2 years of age and older.
The expanded approval was based on data from the phase 3 PRONTO-PUMP-2 trial which evaluated Lyumjev vs Humalog for use in insulin pump therapy in 432 adults with type 1 diabetes.
Low amyloid burden and favorable cognitive outcomes seen with DPP-4i use in Alzheimer disease-related cognitive impairment with diabetes
Screening for gestational diabetes at or after 24 weeks of gestation has moderate net benefit to improve maternal and fetal outcomes
